makes them willing to participate in a trial, even if they understand it will not help them, said Geiger.
According to Simon, in an environment where scientists are many and trial participants are scarce, patient groups are starting to organize their own clinical trial networks and offer them to scientists, “because they realize their registries, their tissue banks, their biobanks, and their experience are the key resources.”
The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
2 Framing the Problem ."
Public Engagement and Clinical Trials: New Models and Disruptive Technologies: Workshop Summary . Washington, DC: The National Academies Press,
Please select a format: